Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cellectar Biosciences, Inc. (CLRB)
USD2.61
-0.02 (-0.76%)
US NASDAQ Healthcare Biotechnology
Address
100 Campus Drive 7932
Florham Park, NJ, US
Florham Park, NJ, US
CEO
James V. Caruso
Website
cellectar.com
IPO
2005-11-10
CIK 1279704 ISIN US15117F8804
Description
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.61
-0.02 (-0.76%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.54
Float Shares
3.01M
Free Float %
94.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.44% | +5.46% | +5.82% | -0.96% | +5.82% | +4.75% | -59.71% | -92.90% | -99.20% | -99.91% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
2.61
Low
11.00
+321.5%
Consensus
11.00
+321.5%
Median
11.00
+321.5%
High
11.00
+321.5%
DCF (Unlevered)
4.38
+67.8%
DCF (Levered)
4.90
+87.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
11.00
+321.5%
|
| Last Quarter | 1 |
11.00
+321.5%
|
| Last Year | 1 |
11.00
+321.5%
|
| All Time | 2 |
11.50
+340.6%
|
Quality scores
Altman Z-Score
-39.84
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+80.1% ★ Q1'26: +69.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +1,103.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+110.7% Q1'26: +176.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q1'26: -0.06× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 3 Rev. Ana. 2 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 15.15M (-100.0%)
|
—
est: 1.75M (-100.0%)
|
—
est: 15.00M (-100.0%)
|
3.80M
3.80M – 3.80M
-74.7% YoY
|
6.77M
6.77M – 6.77M
+78.0% YoY
|
46.38M
46.38M – 46.38M
+585.6% YoY
|
99.05M
99.05M – 99.05M
+113.5% YoY
|
151.65M
151.65M – 151.65M
+53.1% YoY
|
| EBITDA |
-8.19M
|
-51.49M
|
-22.77M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-8.55M
|
-51.78M
|
-22.98M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-5.50M
est: -990.50M (+99.4%)
|
-44.58M
est: -125.76M (+64.6%)
|
-21.79M
est: -24.18M (+9.9%)
|
-5.34M
-5.34M – -5.34M
+77.9% YoY
|
-4.18M
-4.18M – -4.18M
+21.7% YoY
|
-873.8K
-965.1K – -782.5K
+79.1% YoY
|
2.01M
2.01M – 2.01M
+329.9% YoY
|
4.96M
4.96M – 4.96M
+146.8% YoY
|
| SGA |
3.40M
|
25.64M
|
11.48M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-21,090.00
est: -800.00 (-2,536.3%)
|
-36.52
est: -48.38 (+24.5%)
|
-8.35
est: -9.27 (+9.9%)
|
-2.05
-2.05 – -2.05
+77.9% YoY
|
-1.60
-1.60 – -1.60
+21.7% YoY
|
-0.34
-0.37 – -0.30
+79.1% YoY
|
0.77
0.77 – 0.77
+329.9% YoY
|
1.90
1.90 – 1.90
+146.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-11.03M
OE per share TTM
-1,707.21
Owner's Yield
-86.33%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
-122,739.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
7
Total invested
359.2K
Insider transactions (90d)
2
Beneficial owners (>5%)
29
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | S | 6.05M | 9.90% | — | 6.05M | — | 6.05M | CO | ONTARIO, CANADA | 2022-01-21 | ↗ |
| 2 | Consonance Capital Management LP | 4.70M | 9.99% | — | 4.70M | — | — | IA, PN | Delaware USA | 2021-02-17 | ↗ |
| 3 | Consonance Capman GP LLC | 4.59M | 9.99% | — | 4.59M | — | — | HC, OO | Delaware USA | 2021-02-17 | ↗ |
| 4 | Mitchell Blutt | 4.59M | 9.99% | — | 4.59M | — | — | HC, IN | Delaware USA | 2021-02-17 | ↗ |
| 5 | Daniel Mack | 3.23M | 9.90% | — | 3.23M | — | — | HC | USA | 2024-02-14 | ↗ |
| 6 | Nantahala Capital Management, LLC | 3.23M | 9.90% | — | 3.23M | — | — | IA | MA | 2024-02-14 | ↗ |
| 7 | Wilmot B. Harkey | 3.23M | 9.90% | — | 3.23M | — | — | HC | USA | 2024-02-14 | ↗ |
| 8 | Consonance Capital Opportunity Fund Management LP | 2.84M | 6.03% | — | 2.84M | — | — | IA, PN | Delaware USA | 2021-02-17 | ↗ |
| 9 | 27-4413262 | 1.92M | 9.90% | — | — | 1.92M | — | OO | United States | 2023-12-05 | ↗ |
| 10 | Identification Nos. of above persons (. | 1.92M | 9.90% | 1.92M | — | 1.92M | — | IN | United States | 2023-12-05 | ↗ |
| 11 | Laurence W. Lytton | 1.89M | 11.00% | 1.89M | — | 1.89M | — | IN | USA | 2023-12-07 | ↗ |
| 12 | Boxer Capital, LLC | 1.84M | 4.00% | — | 1.84M | — | 1.84M | OO | Bahamas | 2021-02-16 | ↗ |
| 13 | ADAR1 Capital Management GP, LLC | 1.82M | 6.21% | — | 1.82M | — | 1.82M | OO | Citizenship or place of organization | 2024-01-31 | ↗ |
| 14 | ADAR1 Capital Management, LLC | 1.82M | 6.21% | — | 1.82M | — | 1.82M | OO | Citizenship or place of organization | 2024-01-31 | ↗ |
| 15 | ADAR1 Partners, LP | 1.82M | 6.21% | — | 1.82M | — | 1.82M | PN | Citizenship or place of organization | 2024-01-31 | ↗ |
| 16 | Daniel Schneeberger | 1.82M | 6.21% | — | 1.82M | — | 1.82M | IN | Citizenship or place of organization | 2024-01-31 | ↗ |
| 17 | Armistice Capital Master Fund Ltd. | 1.32M | 4.99% | — | 1.32M | — | 1.32M | CO | Delaware | 2020-06-12 | ↗ |
| 18 | Armistice Capital, LLC | 1.32M | 4.99% | — | 1.32M | — | 1.32M | IA, OO | Delaware | 2020-06-12 | ↗ |
| 19 | Steven Boyd | 1.32M | 4.99% | — | 1.32M | — | 1.32M | HC, IN | Delaware | 2020-06-12 | ↗ |
| 20 | Alex Noah Investors, Inc. | 937.6K | 9.99% | — | 937.6K | — | — | CO | Illinois | 2022-10-25 | ↗ |
| 21 | Jonathan I. Cope | 937.6K | 9.99% | — | 937.6K | — | — | IN | United States | 2022-10-25 | ↗ |
| 22 | Joshua B. Scheinfeld | 937.6K | 9.99% | — | 937.6K | — | — | IN | United States | 2022-10-25 | ↗ |
| 23 | Lincoln Park Capital Fund, LLC | 937.6K | 9.99% | — | 937.6K | — | — | OO | Illinois | 2022-10-25 | ↗ |
| 24 | Lincoln Park Capital, LLC | 937.6K | 9.99% | — | 937.6K | — | — | OO | Illinois | 2022-10-25 | ↗ |
| 25 | Rockledge Capital Corporation | 937.6K | 9.99% | — | 937.6K | — | — | CO | Texas | 2022-10-25 | ↗ |
| 26 | Boxer Asset Management Inc. | 931.8K | 9.99% | — | 931.8K | — | 931.8K | CO | Bahamas | 2019-05-28 | ↗ |
| 27 | KEVIN TANG | 637.7K | 6.80% | — | 637.7K | — | 637.7K | IN | UNITED STATES | 2019-05-28 | ↗ |
| 28 | 13G | 600.0K | 6.40% | — | 600.0K | — | 600.0K | CO | Texas | 2019-05-28 | ↗ |
| 29 | Sio Capital Management, LLC 20-4586565 | — | 0.00% | — | — | — | — | IA | Delaware | 2022-02-10 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
7
-13 vs prev Q
New positions
3
Closed positions
16
Increased
4
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BARCLAYS PLC | — -120.5K (-100.0%) | — -257.9K (-100.0%) | 0.00% -7.490 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 95.5K | 0.05% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 337.76 | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 927.38 | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 68.50 | 0.17% |
| 5 | Vanguard Total Stock Market ETF VTI | 0.00% | 158.5K | 0.03% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 347.34 | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 189.22 | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 76.39 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 8.42 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 1.18 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
6
Sells
0
Shares acquired
50.0K
Shares disposed
—
Cash buys
6.00
Cash sales
—
Net activity
+50,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Longcor Jarrod | Officer | P-Purchase | A | Warrants | 26,040 | 2.88 | 75.0K | 36,149 | D | ↗ |
| 2026-05-07 | CARUSO JAMES V | Director / Officer | P-Purchase | A | Warrants | 26,040 | 2.88 | 75.0K | 36,076 | D | ↗ |
| 2025-12-12 | NEIS JOHN | Director | S-Sale | D | Common Stock | 198 | 3.70 | 731.99 | 10 | I | ↗ |
| 2025-07-02 | Longcor Jarrod | Officer | P-Purchase | A | Common Stock | 10,000 | 4.99 | 49.9K | 12,768 | D | ↗ |
| 2025-07-02 | Kolean Chad J | Officer | P-Purchase | A | Common Stock | 5,000 | 4.99 | 25.0K | 6,418 | D | ↗ |
| 2025-07-02 | CARUSO JAMES V | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 4.99 | 49.9K | 11,638 | D | ↗ |
| 2025-02-14 | Swirsky Douglas J | Director | A-Award | A | Stock option (right to buy) | 90,000 | 0.29 | 26.1K | 90,000 | D | ↗ |
| 2025-02-14 | NEIS JOHN | Director | A-Award | A | Stock option (right to buy) | 60,000 | 0.29 | 17.4K | 60,000 | D | ↗ |
| 2025-02-14 | Loren Stefan | Director | A-Award | A | Stock option (right to buy) | 60,000 | 0.29 | 17.4K | 60,000 | D | ↗ |
| 2025-02-14 | Longcor Jarrod | Officer | A-Award | A | Stock option (right to buy) | 500,000 | 0.29 | 145.0K | 500,000 | D | ↗ |
| 2025-02-14 | Kolean Chad J | Officer | A-Award | A | Stock option (right to buy) | 290,000 | 0.29 | 84.1K | 290,000 | D | ↗ |
| 2025-02-14 | DRISCOLL FREDERICK W | Director | A-Award | A | Stock option (right to buy) | 60,000 | 0.29 | 17.4K | 60,000 | D | ↗ |
| 2025-02-14 | Chanan-Khan Asher | Director | A-Award | A | Stock option (right to buy) | 60,000 | 0.29 | 17.4K | 60,000 | D | ↗ |
| 2025-02-14 | CARUSO JAMES V | Director / Officer | A-Award | A | Stock option (right to buy) | 900,000 | 0.29 | 261.0K | 900,000 | D | ↗ |
| 2025-01-10 | Longcor Jarrod | Officer | P-Purchase | A | Common Stock | 30,000 | 0.28 | 8.4K | 83,141 | D | ↗ |
| 2024-06-14 | Swirsky Douglas J | Director | A-Award | A | Stock option (right to buy) | 90,000 | 2.58 | 232.2K | 90,000 | — | ↗ |
| 2024-06-14 | Shustov Andrei | Officer | A-Award | A | Stock option (right to buy) | 260,000 | 2.65 | 689.0K | 260,000 | — | ↗ |
| 2024-06-14 | NEIS JOHN | Director | A-Award | A | Stock option (right to buy) | 60,000 | 2.58 | 154.8K | 60,000 | — | ↗ |
| 2024-06-14 | Loren Stefan | Director | A-Award | A | Stock option (right to buy) | 60,000 | 2.58 | 154.8K | 60,000 | — | ↗ |
| 2024-06-14 | Longcor Jarrod | Officer | A-Award | A | Stock option (right to buy) | 500,000 | 2.65 | 1.33M | 500,000 | — | ↗ |
| 2024-06-14 | Lea Darrell Shane | Officer | A-Award | A | Stock option (right to buy) | 260,000 | 2.65 | 689.0K | 260,000 | — | ↗ |
| 2024-06-14 | Kolean Chad J | Officer | A-Award | A | Stock option (right to buy) | 290,000 | 2.65 | 768.5K | 290,000 | — | ↗ |
| 2024-06-14 | DRISCOLL FREDERICK W | Director | A-Award | A | Stock option (right to buy) | 60,000 | 2.58 | 154.8K | 60,000 | — | ↗ |
| 2024-06-14 | Chanan-Khan Asher | Director | A-Award | A | Stock option (right to buy) | 60,000 | 2.58 | 154.8K | 60,000 | — | ↗ |
| 2024-06-14 | CARUSO JAMES V | Director / Officer | A-Award | A | Stock option (right to buy) | 900,000 | 2.65 | 2.39M | 900,000 | — | ↗ |
| 2023-12-08 | Shustov Andrei | Officer | A-Award | A | Common Stock | 47,856 | 0.00 | — | 55,038 | — | ↗ |
| 2023-12-08 | Longcor Jarrod | Officer | A-Award | A | Common Stock | 42,927 | 0.00 | — | 53,141 | — | ↗ |
| 2023-12-08 | Lea Darrell Shane | Officer | A-Award | A | Common Stock | 39,599 | 0.00 | — | 39,599 | — | ↗ |
| 2023-12-08 | Kolean Chad J | Officer | A-Award | A | Common Stock | 42,554 | 0.00 | — | 42,578 | — | ↗ |
| 2023-12-08 | CARUSO JAMES V | Director / Officer | A-Award | A | Common Stock | 40,596 | 0.00 | — | 49,236 | — | ↗ |
| 2023-06-28 | Swirsky Douglas J | Director | A-Award | A | Stock option (right to buy) | 37,500 | 1.85 | 69.4K | 71,925 | — | ↗ |
| 2023-06-28 | NEIS JOHN | Director | A-Award | A | Stock option (right to buy) | 25,000 | 1.85 | 46.3K | 47,887 | — | ↗ |
| 2023-06-28 | Loren Stefan | Director | A-Award | A | Stock option (right to buy) | 25,000 | 1.85 | 46.3K | 47,885 | — | ↗ |
| 2023-06-28 | DRISCOLL FREDERICK W | Director | A-Award | A | Stock option (right to buy) | 25,000 | 1.85 | 46.3K | 47,650 | — | ↗ |
| 2023-06-28 | Chanan-Khan Asher | Director | A-Award | A | Stock option (right to buy) | 25,000 | 1.85 | 46.3K | 40,600 | — | ↗ |
| 2023-06-23 | Longcor Jarrod | Officer | A-Award | A | Stock option (right to buy) | 144,000 | 1.68 | 241.9K | 144,000 | — | ↗ |
| 2023-06-23 | Lea Darrell Shane | Officer | A-Award | A | Stock option (right to buy) | 100,000 | 1.68 | 168.0K | 100,000 | — | ↗ |
| 2023-06-23 | Kolean Chad J | Officer | A-Award | A | Stock option (right to buy) | 104,000 | 1.68 | 174.7K | 104,000 | — | ↗ |
| 2023-06-23 | CARUSO JAMES V | Director / Officer | A-Award | A | Stock option (right to buy) | 261,000 | 1.68 | 438.5K | 261,000 | — | ↗ |
| 2023-02-15 | Shustov Andrei | Officer | A-Award | A | Stock option (right to buy) | 100,000 | 1.67 | 167.0K | 100,000 | — | ↗ |
| 2023-01-17 | Longcor Jarrod | Officer | A-Award | A | Stock option (right to buy) | 144,000 | 0.00 | — | 144,000 | — | ↗ |
| 2023-01-17 | Kolean Chad J | Officer | A-Award | A | Stock option (right to buy) | 104,000 | 0.00 | — | 104,000 | — | ↗ |
| 2023-01-17 | CARUSO JAMES V | Officer | A-Award | A | Stock option (right to buy) | 261,000 | 0.00 | — | 261,000 | — | ↗ |
| 2022-11-21 | Lea Darrell Shane | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2022-06-24 | Swirsky Douglas J | Director | A-Award | A | Stock option (right to buy) | 11,700 | 0.00 | — | 11,700 | — | ↗ |
| 2022-06-24 | NEIS JOHN | Director | A-Award | A | Stock option (right to buy) | 7,800 | 0.00 | — | 7,800 | — | ↗ |
| 2022-06-24 | Loren Stefan | Director | A-Award | A | Stock option (right to buy) | 7,800 | 0.00 | — | 7,800 | — | ↗ |
| 2022-06-24 | DRISCOLL FREDERICK W | Director | A-Award | A | Stock option (right to buy) | 7,800 | 0.00 | — | 7,800 | — | ↗ |
| 2022-06-24 | Chanan-Khan Asher | Director | A-Award | A | Stock option (right to buy) | 7,800 | 0.00 | — | 7,800 | — | ↗ |
| 2022-02-24 | Kolean Chad J | Officer | — | D | Common Stock | 0 | 0.00 | — | 240 | — | ↗ |
| 2022-02-22 | Kolean Chad J | — | A-Award | A | Stock option (right to buy) | 150,000 | 0.49 | 73.5K | 150,000 | — | ↗ |
| 2022-01-25 | Longcor Jarrod | Officer | A-Award | A | Stock option (right to buy) | 475,000 | 0.55 | 261.3K | 475,000 | — | ↗ |
| 2022-01-25 | Elefant Dov | Officer | A-Award | A | Stock option (right to buy) | 422,000 | 0.55 | 232.1K | 422,000 | — | ↗ |
| 2022-01-25 | CARUSO JAMES V | Director / Officer | A-Award | A | Stock option (right to buy) | 1,419,000 | 0.55 | 780.5K | 1,419,000 | — | ↗ |
| 2021-09-14 | Swirsky Douglas J | Director | P-Purchase | A | Common Stock | 25,000 | 1.04 | 26.0K | 25,000 | — | ↗ |
| 2021-09-03 | DRISCOLL FREDERICK W | Director | P-Purchase | A | Common Stock | 19,417 | 1.04 | 20.2K | 19,417 | — | ↗ |
| 2021-06-30 | Swirsky Douglas J | Director | A-Award | A | Stock option (right to buy) | 117,000 | 1.19 | 139.2K | 117,000 | — | ↗ |
| 2021-06-30 | NEIS JOHN | Director | A-Award | A | Stock option (right to buy) | 78,000 | 1.19 | 92.8K | 78,000 | — | ↗ |
| 2021-06-30 | Loren Stefan | Director | A-Award | A | Stock option (right to buy) | 78,000 | 1.19 | 92.8K | 78,000 | — | ↗ |
| 2021-06-30 | DRISCOLL FREDERICK W | Director | A-Award | A | Stock option (right to buy) | 78,000 | 1.19 | 92.8K | 78,000 | — | ↗ |
| 2021-06-30 | Chanan-Khan Asher | Director | A-Award | A | Stock option (right to buy) | 78,000 | 1.19 | 92.8K | 78,000 | — | ↗ |
| 2021-06-23 | Chanan-Khan Asher | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-03-18 | NEIS JOHN | Director | S-Sale | D | Series A Warrants | 23,232 | 30.40 | 706.3K | 0 | — | ↗ |
| 2021-03-17 | NEIS JOHN | Director | S-Sale | D | Series A Warrants | 58,640 | 30.40 | 1.78M | 23,232 | — | ↗ |
| 2021-03-16 | NEIS JOHN | Director | S-Sale | D | Series A Warrants | 100,515 | 30.40 | 3.06M | 81,872 | — | ↗ |
| 2021-03-15 | NEIS JOHN | Director | S-Sale | D | Series A Warrants | 11,200 | 30.40 | 340.5K | 182,387 | — | ↗ |
| 2021-03-12 | NEIS JOHN | Director | S-Sale | D | Series A Warrants | 41,155 | 30.40 | 1.25M | 193,587 | — | ↗ |
| 2021-03-04 | Longcor Jarrod | Officer | A-Award | A | Stock option (right to buy) | 450,000 | 1.74 | 783.0K | 450,000 | — | ↗ |
| 2021-03-04 | Friend John E. II | Officer | A-Award | A | Stock option (right to buy) | 330,000 | 1.74 | 574.2K | 330,000 | — | ↗ |
| 2021-03-04 | Elefant Dov | Officer | A-Award | A | Stock option (right to buy) | 430,000 | 1.74 | 748.2K | 430,000 | — | ↗ |
| 2021-03-04 | CARUSO JAMES V | Director / Officer | A-Award | A | Stock option (right to buy) | 1,600,000 | 1.74 | 2.78M | 1,600,000 | — | ↗ |
| 2020-12-28 | Longcor Jarrod | Officer | P-Purchase | A | Common Stock | 29,630 | 1.35 | 40.0K | 102,148 | — | ↗ |
| 2020-12-28 | Elefant Dov | Officer | P-Purchase | A | Common Stock | 7,407 | 1.35 | 10.0K | 11,755 | — | ↗ |
| 2020-12-28 | CARUSO JAMES V | Director / Officer | P-Purchase | A | Common Stock | 37,037 | 1.35 | 50.0K | 81,301 | — | ↗ |
| 2020-07-01 | Friend John E. II | Officer | A-Award | A | Stock option (right to buy) | 100,000 | 1.34 | 134.0K | 100,000 | — | ↗ |
| 2020-06-24 | Swirsky Douglas J | Director | A-Award | A | Stock option (right to buy) | 80,000 | 1.28 | 102.4K | 80,000 | — | ↗ |
| 2020-06-24 | NEIS JOHN | Director | A-Award | A | Stock option (right to buy) | 50,000 | 1.28 | 64.0K | 50,000 | — | ↗ |
| 2020-06-24 | Loren Stefan | Director | A-Award | A | Stock option (right to buy) | 50,000 | 1.28 | 64.0K | 50,000 | — | ↗ |
| 2020-06-24 | HILL STEPHEN A | Director | A-Award | A | Stock option (right to buy) | 50,000 | 1.28 | 64.0K | 50,000 | — | ↗ |
| 2020-06-24 | DRISCOLL FREDERICK W | Director | A-Award | A | Stock option (right to buy) | 50,000 | 1.28 | 64.0K | 50,000 | — | ↗ |
| 2020-06-05 | Longcor Jarrod | Officer | P-Purchase | A | Common Stock | 65,218 | 1.15 | 74.7K | 72,518 | — | ↗ |
| 2020-06-05 | Elefant Dov | Officer | P-Purchase | A | Common Stock | 4,348 | 1.15 | 5.0K | 4,348 | — | ↗ |
| 2020-06-05 | CARUSO JAMES V | Director / Officer | P-Purchase | A | Common Stock | 21,740 | 1.15 | 24.9K | 44,264 | — | ↗ |
| 2020-06-04 | HILL STEPHEN A | Director | P-Purchase | A | Common Stock | 18,000 | 1.08 | 19.4K | 18,000 | — | ↗ |
| 2020-02-03 | Longcor Jarrod | Officer | A-Award | A | Common stock | 40,000 | 2.71 | 108.4K | 40,000 | — | ↗ |
| 2020-02-03 | Elefant Dov | Officer | A-Award | A | Common stock | 10,000 | 2.71 | 27.1K | 10,000 | — | ↗ |
| 2020-02-03 | CARUSO JAMES V | Director / Officer | A-Award | A | Stock option (right to buy) | 100,000 | 2.71 | 271.0K | 100,000 | — | ↗ |
| 2020-01-06 | Grachev Igor D | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 2.46 | 196.8K | 80,000 | — | ↗ |
| 2019-09-10 | Elefant Dov | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 2.32 | 208.8K | 90,000 | — | ↗ |
| 2019-06-13 | Swirsky Douglas J | Director | A-Award | A | Stock option (right to buy) | 9,750 | 2.15 | 21.0K | 9,750 | — | ↗ |
| 2019-06-13 | NEIS JOHN | Director | A-Award | A | Stock option (right to buy) | 6,500 | 2.15 | 14.0K | 6,500 | — | ↗ |
| 2019-06-13 | Loren Stefan | Director | A-Award | A | Stock option (right to buy) | 6,500 | 2.15 | 14.0K | 6,500 | — | ↗ |
| 2019-06-13 | HILL STEPHEN A | Director | A-Award | A | Stock option (right to buy) | 6,500 | 2.15 | 14.0K | 6,500 | — | ↗ |
| 2019-06-13 | DRISCOLL FREDERICK W | Director | A-Award | A | Stock option (right to buy) | 6,500 | 2.15 | 14.0K | 6,500 | — | ↗ |
| 2019-03-09 | Bernhardt Charles Thomas III | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-02-28 | Longcor Jarrod | Officer | P-Purchase | A | Common Stock | 100 | 2.00 | 200.25 | 7,300 | — | ↗ |
| 2019-01-17 | POSNER BRIAN M | Officer | A-Award | A | Stock option (right to buy) | 30,000 | 1.99 | 59.7K | 30,000 | — | ↗ |
| 2019-01-17 | Longcor Jarrod | Officer | A-Award | A | Stock option (right to buy) | 30,000 | 1.99 | 59.7K | 30,000 | — | ↗ |
| 2019-01-17 | CARUSO JAMES V | Director / Officer | A-Award | A | Stock option (right to buy) | 75,000 | 1.99 | 149.3K | 75,000 | — | ↗ |
| 2018-11-30 | CARUSO JAMES V | Director / Officer | P-Purchase | A | Common Stock, par value $0.00001 per share | 1,000 | 2.28 | 2.3K | 22,354 | — | ↗ |
| 2018-11-29 | HILL STEPHEN A | Director | S-Sale | A | Series A Warrants | 9,390 | 30.40 | 285.5K | 0 | — | ↗ |
| 2018-10-12 | Swirsky Douglas J | Director | A-Award | A | Stock option (right to buy) | 19,500 | 2.61 | 50.9K | 19,500 | — | ↗ |
| 2018-10-12 | POSNER BRIAN M | Officer | A-Award | A | Stock option (right to buy) | 54,000 | 2.61 | 140.9K | 54,000 | — | ↗ |
| 2018-10-12 | NEIS JOHN | Director | A-Award | A | Stock option (right to buy) | 13,000 | 2.61 | 33.9K | 13,000 | — | ↗ |
| 2018-10-12 | Loren Stefan | Director | A-Award | A | Stock option (right to buy) | 13,000 | 2.61 | 33.9K | 13,000 | — | ↗ |
| 2018-10-12 | Longcor Jarrod | Officer | A-Award | A | Stock option (right to buy) | 63,000 | 2.61 | 164.4K | 63,000 | — | ↗ |
| 2018-10-12 | HILL STEPHEN A | Director | A-Award | A | Stock option (right to buy) | 13,000 | 2.61 | 33.9K | 13,000 | — | ↗ |
| 2018-10-12 | Friend John E. II | Officer | A-Award | A | Stock option (right to buy) | 63,000 | 2.61 | 164.4K | 63,000 | — | ↗ |
| 2018-10-12 | DRISCOLL FREDERICK W | Director | A-Award | A | Stock option (right to buy) | 13,000 | 2.61 | 33.9K | 13,000 | — | ↗ |
| 2018-10-12 | CARUSO JAMES V | Director / Officer | A-Award | A | Stock option (right to buy) | 150,000 | 2.61 | 391.5K | 150,000 | — | ↗ |
| 2018-08-16 | Longcor Jarrod | Officer | P-Purchase | A | Common Stock | 500 | 2.71 | 1.4K | 7,200 | — | ↗ |
| 2018-04-06 | POSNER BRIAN M | Officer | A-Award | A | Stock option (right to buy) | 80,000 | 1.17 | 93.6K | 80,000 | — | ↗ |
| 2018-04-01 | POSNER BRIAN M | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-03-13 | Longcor Jarrod | Officer | S-Sale | D | Common Stock | 13,000 | 1.18 | 15.4K | 67,000 | — | ↗ |
| 2018-03-12 | CARUSO JAMES V | Director / Officer | S-Sale | D | Common Stock | 34,000 | 1.20 | 40.7K | 213,548 | — | ↗ |
| 2017-11-14 | NEIS JOHN | Director | S-Sale | D | Common Stock, par value $0.00001 per share | 5,214 | 1.49 | 7.8K | 626,103 | — | ↗ |
| 2017-09-18 | Longcor Jarrod | Officer | A-Award | A | Employee Stock Option (right to buy) | 25,000 | 1.83 | 45.8K | 25,000 | — | ↗ |
| 2017-09-05 | Hamill John P. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-05-31 | Swirsky Douglas J | Director | A-Award | A | Stock option (right to buy) | 10,000 | 1.74 | 17.4K | 10,000 | — | ↗ |
| 2017-05-31 | NEIS JOHN | Director | A-Award | A | Stock option (right to buy) | 10,000 | 1.74 | 17.4K | 10,000 | — | ↗ |
| 2017-05-31 | Loren Stefan | Director | A-Award | A | Stock option (right to buy) | 10,000 | 1.74 | 17.4K | 10,000 | — | ↗ |
| 2017-05-31 | HILL STEPHEN A | Director | A-Award | A | Stock option (right to buy) | 10,000 | 1.74 | 17.4K | 10,000 | — | ↗ |
| 2017-05-31 | DRISCOLL FREDERICK W | Director | A-Award | A | Stock option (right to buy) | 10,000 | 1.74 | 17.4K | 10,000 | — | ↗ |
| 2017-04-18 | Longcor Jarrod | Officer | A-Award | A | Common stock | 80,000 | 0.00 | — | 80,000 | — | ↗ |
| 2017-04-18 | Kolean Chad J | Officer | A-Award | A | Common stock | 80,000 | 0.00 | — | 80,000 | — | ↗ |
| 2017-04-18 | CARUSO JAMES V | Director / Officer | A-Award | A | Common stock | 200,000 | 0.00 | — | 247,548 | — | ↗ |
| 2017-04-17 | Friend John E. II | Officer | A-Award | A | Common stock | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2017-04-10 | Swirsky Douglas J | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-04-10 | DRISCOLL FREDERICK W | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-11-29 | NEIS JOHN | Director | P-Purchase | A | Common Stock, par value $0.00001 per share | 333,333 | 1.49 | 496.7K | 631,317 | — | ↗ |
| 2016-10-31 | Hertzberg Richard | — | S-Sale | D | Cellectar Biosciences, Inc. common stock (CLRB) | 21,000 | 2.03 | 42.6K | 280,000 | — | ↗ |
| 2016-08-09 | Hertzberg Richard | — | S-Sale | D | Cellectar Biosciences Inc. Warrant (CLRBW) | 40,916 | 46.80 | 1.91M | 0 | — | ↗ |
| 2016-07-15 | Longcor Jarrod | Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 2.93 | 219.8K | 75,000 | — | ↗ |
| 2016-07-05 | NEIS JOHN | Director | A-Award | A | Stock option (right to buy) | 22,500 | 3.34 | 75.2K | 24,750 | — | ↗ |
| 2016-07-05 | Loren Stefan | Director | A-Award | A | Stock option (right to buy) | 22,500 | 3.34 | 75.2K | 23,500 | — | ↗ |
| 2016-07-05 | HILL STEPHEN A | Director | A-Award | A | Stock option (right to buy) | 22,500 | 3.34 | 75.2K | 25,434 | — | ↗ |
| 2016-05-12 | Weichert Jamey P | Officer | A-Award | A | Stock option (right to buy) | 40,000 | 1.48 | 59.2K | 42,895 | — | ↗ |
| 2016-05-12 | Kolean Chad J | Officer | A-Award | A | Stock option (right to buy) | 50,000 | 1.48 | 74.0K | 52,000 | — | ↗ |
| 2016-05-12 | CARUSO JAMES V | Director / Officer | A-Award | A | Stock option (right to buy) | 200,000 | 1.48 | 296.0K | 237,500 | — | ↗ |
| 2016-04-21 | Hertzberg Richard | — | P-Purchase | A | Cellectar Biosciences, Inc. | 3,758 | 1.90 | 7.1K | 301,000 | — | ↗ |
| 2016-04-20 | WISCONSIN ALUMNI RESEARCH FOUNDATION | 10% Owner | — | D | Common Stock Purchase Warrants | 469,484 | 3.04 | 1.43M | 0 | — | ↗ |
| 2016-04-20 | NEIS JOHN | Director | P-Purchase | A | Common Stock, par value $0.00001 per share | 234,742 | 2.12 | 497.7K | 297,984 | — | ↗ |
| 2016-04-20 | HILL STEPHEN A | Director | P-Purchase | A | Series A Warrants | 9,390 | 3.04 | 28.5K | 9,920 | — | ↗ |
| 2016-04-20 | CARUSO JAMES V | Director / Officer | P-Purchase | A | Common Stock, par value $0.00001 per share | 46,948 | 2.12 | 99.5K | 47,548 | — | ↗ |
| 2016-04-20 | BERNS PAUL L | Director | P-Purchase | A | Common Stock, par value $0.00001 per share | 117,371 | 2.12 | 248.8K | 117,371 | — | ↗ |
| 2016-04-15 | Hertzberg Richard | — | P-Purchase | A | Cellectar Biosciences, Inc. Series A Warrant (CLRBZ) | 234,742 | 3.04 | 713.6K | 41,915 | — | ↗ |
| 2016-04-14 | WISCONSIN ALUMNI RESEARCH FOUNDATION | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 469,484 | — | ↗ |
| 2015-12-31 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 35,253 | 0.70 | 24.5K | 0 | — | ↗ |
| 2015-12-30 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 64,747 | 0.69 | 44.5K | 35,253 | — | ↗ |
| 2015-12-29 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 82,847 | 0.69 | 57.4K | 100,000 | — | ↗ |
| 2015-12-28 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 150,975 | 0.69 | 104.2K | 182,847 | — | ↗ |
| 2015-12-24 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 216,991 | 0.76 | 164.8K | 333,822 | — | ↗ |
| 2015-12-22 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 7,938 | 0.90 | 7.2K | 550,813 | — | ↗ |
| 2015-12-21 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 20,621 | 0.92 | 19.0K | 558,751 | — | ↗ |
| 2015-12-18 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 7,000 | 0.90 | 6.3K | 579,372 | — | ↗ |
| 2015-12-17 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 18,240 | 0.88 | 16.1K | 586,372 | — | ↗ |
| 2015-12-16 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 52,985 | 0.86 | 45.8K | 604,612 | — | ↗ |
| 2015-12-15 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 44,965 | 0.82 | 37.1K | 657,597 | — | ↗ |
| 2015-12-04 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 1,000 | 1.14 | 1.1K | 752,512 | — | ↗ |
| 2015-12-01 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 42,110 | 1.04 | 43.8K | 753,512 | — | ↗ |
| 2015-11-25 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 4,378 | 1.20 | 5.3K | 795,622 | — | ↗ |
| 2015-11-24 | CARUSO JAMES V | Director / Officer | P-Purchase | A | Common Stock, par value $0.00001 per share | 1,000 | 1.30 | 1.3K | 6,000 | — | ↗ |
| 2015-11-24 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 67,102 | 1.27 | 85.5K | 800,000 | — | ↗ |
| 2015-11-23 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 106,700 | 1.21 | 129.2K | 867,102 | — | ↗ |
| 2015-11-20 | CARUSO JAMES V | Director / Officer | P-Purchase | A | Common Stock, par value $0.00001 per share | 1,000 | 1.16 | 1.2K | 5,000 | — | ↗ |
| 2015-11-20 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 88,745 | 1.15 | 102.2K | 973,802 | — | ↗ |
| 2015-11-19 | CARUSO JAMES V | Director / Officer | P-Purchase | A | Common Stock, par value $0.00001 per share | 2,000 | 1.50 | 3.0K | 4,000 | — | ↗ |
| 2015-11-19 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 8,061 | 1.38 | 11.1K | 10,625,547 | — | ↗ |
| 2015-11-18 | CARUSO JAMES V | Director / Officer | P-Purchase | A | Common Stock, par value $0.00001 per share | 2,000 | 1.39 | 2.8K | 2,000 | — | ↗ |
| 2015-10-28 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 99 | 2.00 | 198.00 | 1,070,608 | — | ↗ |
| 2015-10-23 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 2,000 | 2.00 | 4.0K | 1,070,707 | — | ↗ |
| 2015-10-22 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 6,866 | 2.00 | 13.7K | 1,072,707 | — | ↗ |
| 2015-10-06 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 2,554 | 2.00 | 5.1K | 1,079,573 | — | ↗ |
| 2015-10-05 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 2,800 | 2.11 | 5.9K | 1,082,127 | — | ↗ |
| 2015-10-02 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 4,700 | 2.00 | 9.4K | 1,084,927 | — | ↗ |
| 2015-10-01 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 21,600 | 2.06 | 44.5K | 1,089,627 | — | ↗ |
| 2015-09-30 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 6,340 | 2.00 | 12.7K | 1,111,227 | — | ↗ |
| 2015-09-29 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 1,701 | 2.15 | 3.7K | 1,117,567 | — | ↗ |
| 2015-09-28 | AWM Investment Company, Inc. | 10% Owner | S-Sale | D | Common Stock | 10,000 | 2.65 | 26.5K | 1,119,268 | — | ↗ |
| 2015-06-15 | Loren Stefan | Director | — | D | Employee Stock Option (right to buy) | 10,000 | 2.64 | 26.4K | 0 | — | ↗ |
| 2015-06-15 | CARUSO JAMES V | Director / Officer | — | D | Employee Stock Option (right to buy) | 375,000 | 2.64 | 990.0K | 0 | — | ↗ |
| 2015-06-09 | NEIS JOHN | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 2.64 | 13.2K | 5,000 | — | ↗ |
| 2015-06-09 | HILL STEPHEN A | Director | A-Award | A | Stock option (right to buy) | 5,000 | 2.64 | 13.2K | 5,000 | — | ↗ |
| 2015-06-09 | BERNS PAUL L | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 2.64 | 13.2K | 5,000 | — | ↗ |
| 2015-02-26 | NEIS JOHN | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 2.69 | 13.5K | 5,000 | — | ↗ |
| 2015-02-26 | HILL STEPHEN A | Director | A-Award | A | Stock option (right to buy) | 5,500 | 2.69 | 14.8K | 5,500 | — | ↗ |
| 2015-02-26 | Genn John Patrick | Officer | A-Award | A | Stock option (right to buy) | 10,000 | 2.69 | 26.9K | 10,000 | — | ↗ |
| 2015-02-26 | BERNS PAUL L | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 2.69 | 13.5K | 5,000 | — | ↗ |
| 2015-02-03 | MARXE AUSTIN W & GREENHOUSE DAVID M | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-02-03 | AWM Investment Company, Inc. | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-11-24 | Szakacs Cameron | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-09-08 | MARXE AUSTIN W & GREENHOUSE DAVID M | 10% Owner | P-Purchase | A | Common Stock | 182 | 3.00 | 546.00 | 1,142,368 | — | ↗ |
| 2014-09-08 | Genn John Patrick | Officer | P-Purchase | A | Stock purchase warrant (right to buy) | 10,000 | 4.68 | 46.8K | 77,083 | — | ↗ |
| 2014-08-29 | Genn John Patrick | Officer | P-Purchase | A | Stock purchase warrant (right to buy) | 15,000 | 4.68 | 70.2K | 67,083 | — | ↗ |
| 2014-08-28 | Genn John Patrick | Officer | P-Purchase | A | Stock purchase warrant (right to buy) | 22,000 | 4.68 | 103.0K | 52,083 | — | ↗ |
| 2014-08-27 | Genn John Patrick | Officer | P-Purchase | A | Stock purchase warrant (right to buy) | 3,000 | 4.68 | 14.0K | 30,083 | — | ↗ |
| 2014-08-22 | MARXE AUSTIN W & GREENHOUSE DAVID M | 10% Owner | P-Purchase | A | Common Stock | 5,699 | 3.00 | 17.1K | 1,142,186 | — | ↗ |
| 2014-08-20 | Pedder Simon | Director / Officer | P-Purchase | A | Common Stock, par value $0.00001 per share | 13,300 | 3.75 | 49.9K | 13,300 | — | ↗ |
| 2014-08-20 | NEIS JOHN | Director | S-Sale | D | Convertible Debenture (right to buy) | 50,000 | 10.00 | 500.0K | 0 | — | ↗ |
| 2014-08-20 | Hertzberg Richard | 10% Owner | P-Purchase | A | Cellectar Biosciences Inc. Warrant (CLRBW) | 409,158 | 4.68 | 1.91M | 409,158 | — | ↗ |
Executive team
Top executives
Shares Outstanding
3.19M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | James V. Caruso President and Chief Executive Officer | 650.0K | — | — | 2.21M | 178.8K | — | 3.04M | 72.76% | ↗ |
| 2 | 2024 | Jarrod Longcor Chief Operating Officer | 500.0K | — | — | 1.23M | 100.0K | — | 1.83M | 67.21% | ↗ |
| 3 | 2024 | Chad J. Kolean Chief Financial Officer | 425.0K | — | — | 713.4K | 85.0K | — | 1.22M | 58.31% | ↗ |
| 4 | 2023 | James V. Caruso President and Chief Executive Officer | 600.0K | — | 107.6K | 715.1K | 450.0K | 92.4K | 1.97M | 41.87% | ↗ |
| 5 | 2023 | Jarrod Longcor Chief Operating Officer | 480.0K | — | 113.8K | 394.6K | 288.0K | 86.2K | 1.36M | 37.31% | ↗ |
| 6 | 2023 | Chad J. Kolean Chief Financial Officer | 390.0K | — | 112.8K | 285.0K | 234.0K | 87.2K | 1.11M | 35.87% | ↗ |
| 7 | 2022 | James V. Caruso President and Chief Executive Officer | 569.3K | — | — | 616.7K | 277.2K | — | 1.46M | 42.15% | ↗ |
| 8 | 2022 | Jarrod Longcor Chief Operating Officer | 450.0K | — | — | 206.4K | 175.3K | — | 831.8K | 24.82% | ↗ |
| 9 | 2022 | Chad J. Kolean Chief Financial Officer | 290.4K | — | — | 58.1K | 113.1K | — | 461.6K | 12.58% | ↗ |
| 10 | 2021 | James V. Caruso President and Chief Executive Officer | 522.5K | — | — | 1.47M | 156.8K | — | 2.15M | 68.43% | ↗ |
| 11 | 2021 | Jarrod Longcor Chief Operating Officer | 385.0K | — | — | 414.0K | 92.4K | — | 891.4K | 46.44% | ↗ |
| 12 | 2021 | Jarrod Longcor Chief Operating Officer and Former Chief Business Officer | 385.0K | — | — | 414.0K | 92.4K | — | 891.4K | 46.44% | ↗ |
| 13 | 2021 | Dov Elefant Former Vice President and Chief Financial Officer | 356.9K | — | — | 395.6K | 85.7K | — | 838.2K | 47.20% | ↗ |
| 14 | 2021 | John E. Friend II, M.D. Former Vice President and Chief Medical Officer | 376.4K | — | — | 303.6K | — | 26.6K | 706.5K | 42.97% | ↗ |
| 15 | 2020 | James V. Caruso President and Chief Executive Officer | 475.0K | — | — | 208.7K | 332.5K | — | 1.02M | 20.54% | ↗ |
| 16 | 2020 | Igor Grachev, M.D., Ph.D. Former Chief Medical Officer | 192.6K | — | — | 152.0K | — | 239.5K | 584.1K | 26.02% | ↗ |
| 17 | 2020 | Jarrod Longcor Chief Operating Officer and Former Chief Business Officer | 353.2K | — | — | 83.5K | 137.8K | — | 574.5K | 14.53% | ↗ |
| 18 | 2020 | Jarrod Longcor Chief Business Officer | 353.2K | 137.8K | — | 83.5K | — | — | 574.5K | 14.53% | ↗ |
| 19 | 2020 | Dov Elefant Former Vice President and Chief Financial Officer | 324.5K | — | — | 20.9K | 126.5K | — | 471.9K | 4.42% | ↗ |
| 20 | 2020 | Dov Elefant Vice President and Chief Financial Officer | 324.5K | 126.5K | — | 20.9K | — | — | 471.9K | 4.42% | ↗ |
| 21 | 2020 | John E. Friend II, M.D. Former Vice President and Chief Medical Officer | 200.0K | — | — | 108.3K | 78.0K | — | 386.3K | 28.04% | ↗ |
| 22 | 2019 | James V. Caruso President and Chief Executive Officer | 450.5K | 214.0K | — | 270.0K | — | — | 934.5K | 28.89% | ↗ |
| 23 | 2019 | Jarrod Longcor Chief Business Officer | 333.3K | 95.0K | — | 111.1K | — | — | 539.3K | 20.60% | ↗ |
| 24 | 2019 | Dov Elefant Vice President and Chief Financial Officer | 97.5K | 57.8K | — | 157.1K | — | — | 312.4K | 50.30% | ↗ |
| 25 | 2019 | Charles T. Bernhardt Former Interim Chief Financial Officer | — | — | — | — | — | 187.3K | 187.3K | 0.00% | ↗ |
| 26 | 2019 | Brian Posner Former Vice President and Chief Financial Officer | 63.2K | — | — | — | — | — | 63.2K | 0.00% | ↗ |
| 27 | 2018 | James V. Caruso President and Chief Executive Officer | 425.0K | 204.5K | — | 140.5K | — | — | 770.0K | 18.24% | ↗ |
| 28 | 2018 | Jarrod Longcor Chief Business Officer | 325.0K | 93.8K | — | 59.0K | — | — | 477.9K | 12.36% | ↗ |
| 29 | 2018 | Brian Posner Former Vice President and Chief Financial Officer | 225.0K | 65.0K | — | 127.4K | — | — | 417.4K | 30.53% | ↗ |
| 30 | 2018 | Dr. John E. Friend, MD Former Vice President and Chief Medical Officer | 339.5K | — | — | 59.0K | — | — | 398.5K | 14.82% | ↗ |
| 31 | 2018 | John P. Hamill Former Interim Chief Financial Officer | — | — | — | — | — | 11.7K | 11.7K | 0.00% | ↗ |
| 32 | 2017 | James V. Caruso President and Chief Executive Officer | 410.0K | 164.0K | 420.0K | — | — | — | 994.0K | 42.25% | ↗ |
| 33 | 2017 | Jarrod Longcor Chief Business Officer | 304.3K | 73.0K | 206.1K | — | — | — | 583.5K | 35.32% | ↗ |
| 34 | 2017 | Dr. John E. Friend, MD Former Vice President of Business Development | 251.5K | 110.4K | 208.0K | — | — | — | 569.8K | 36.50% | ↗ |
| 35 | 2017 | Dr. John E. Friend, MD Former Vice President and Chief Medical Officer | 251.5K | 110.4K | 208.0K | — | — | — | 569.8K | 36.50% | ↗ |
| 36 | 2017 | Chad J. Kolean Vice President, Chief Financial Officer and Treasurer | 170.7K | — | 168.0K | — | — | — | 338.7K | 49.61% | ↗ |
| 37 | 2017 | John P. Hamill Interim Chief Financial Officer | — | — | — | — | — | 169.8K | 169.8K | 0.00% | ↗ |
| 38 | 2017 | John P. Hamill Former Interim Chief Financial Officer | — | — | — | — | — | 169.8K | 169.8K | 0.00% | ↗ |
| 39 | 2016 | James V. Caruso President and Chief Executive Officer | 382.5K | 210.4K | — | 238.5K | — | — | 831.3K | 28.68% | ↗ |
| 40 | 2016 | Jarrod Longcor Chief Business Officer | 131.2K | 43.3K | — | 176.9K | — | 112.8K | 464.2K | 38.11% | ↗ |
| 41 | 2016 | Jarrod Longcor Senior Vice President, Corporate Development and Operations | 131.2K | — | — | 176.9K | — | 112.8K | 420.9K | 42.03% | ↗ |
| 42 | 2016 | Chad J. Kolean Vice President, Chief Financial Officer and Treasurer | 235.0K | 77.6K | — | 59.6K | — | — | 372.2K | 16.02% | ↗ |
| 43 | 2016 | J. Patrick Genn Former Vice President of Business Development | 40.6K | — | — | — | — | 30.3K | 70.9K | 0.00% | ↗ |
| 44 | 2015 | James V. Caruso President and Chief Executive Officer | 204.5K | — | — | 808.8K | — | 100.7K | 1.11M | 72.60% | ↗ |
| 45 | 2015 | James V. Caruso Chief Executive Officer | 204.5K | — | — | 808.8K | — | 100.7K | 1.11M | 72.60% | ↗ |
| 46 | 2015 | Chad J. Kolean Chief Financial Officer | 217.5K | — | — | — | — | 22.2K | 239.7K | 0.00% | ↗ |
| 47 | 2015 | Chad J. Kolean Vice President, Chief Financial Officer and Treasurer | 217.5K | — | — | — | — | 22.2K | 239.7K | 0.00% | ↗ |
| 48 | 2015 | J. Patrick Genn Former Vice President of Business Development | 203.7K | — | — | 22.0K | — | — | 225.7K | 9.77% | ↗ |
| 49 | 2015 | Kathryn M. McNeil Former Vice President of Investor Relations | 135.7K | — | — | — | — | 77.8K | 213.5K | 0.00% | ↗ |
| 50 | 2015 | Simon Pedder, Ph.D. Former Chief Executive Officer | 160.4K | — | — | — | — | 564.00 | 161.0K | 0.00% | ↗ |
| 51 | 2014 | Simon Pedder, Ph.D. Chief Executive Officer | 262.5K | — | — | — | — | 90.8K | 353.3K | 0.00% | ↗ |
| 52 | 2014 | Simon Pedder, Ph.D. Former Chief Executive Officer | 262.5K | — | — | — | — | 90.8K | 353.3K | 0.00% | ↗ |
| 53 | 2014 | Joanne M. Protano Former Chief Financial Officer | 111.5K | — | — | 35.2K | — | 116.8K | 263.5K | 13.37% | ↗ |
| 54 | 2014 | Chad J. Kolean Chief Financial Officer | 127.9K | — | — | 122.5K | — | 657.00 | 251.0K | 48.80% | ↗ |
| 55 | 2014 | Chad J. Kolean Chief Financial Officer | 127.9K | — | — | 122.5K | — | 657.00 | 251.0K | 48.80% | ↗ |
| 56 | 2014 | Kathryn M. McNeil Vice President of Investor Relations | 225.0K | — | — | — | — | 21.1K | 246.1K | 0.00% | ↗ |
| 57 | 2014 | Kathryn M. McNeil Former Vice President of Investor Relations | 225.0K | — | — | — | — | 21.1K | 246.1K | 0.00% | ↗ |
| 58 | 2014 | J. Patrick Genn Former Vice President of Business Development | 203.7K | — | — | — | — | 1.1K | 204.8K | 0.00% | ↗ |
| 59 | 2013 | Simon Pedder, Ph.D. Chief Executive Officer | — | — | — | 927.0K | — | 90.0K | 1.02M | 91.15% | ↗ |
| 60 | 2013 | Joanne M. Protano Former Chief Financial Officer | 224.8K | 67.4K | — | — | — | — | 292.2K | 0.00% | ↗ |
| 61 | 2013 | Kathryn M. McNeil Vice President of Investor Relations | 31.0K | — | — | 132.4K | — | — | 163.3K | 81.03% | ↗ |
| 62 | 2013 | Chad J. Kolean Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James V. Caruso | President, Chief Executive Officer & Director | 845.0K | male |
| Jarrod Longcor | Chief Operating Officer | 650.0K | male |
| Chad J. Kolean | Vice President, Chief Financial Officer & Secretary | 552.5K | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CLRB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
